(Z)-2-fluoro-8-(3-(4-(trifluoromethoxy)phenyl)ureido)oct-2-enamide | 1168115-94-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-2-fluoro-8-(3-(4-(trifluoromethoxy)phenyl)ureido)oct-2-enamide
• 英文别名: (Z)-2-fluoro-8-[[4-(trifluoromethoxy)phenyl]carbamoylamino]oct-2-enamide
• CAS: 1168115-94-3
• 化学式: C₁₆H₁₉F₄N₃O₃
• 分子量: 377.339
• InChiKey: ZLEWPBVDRKKCRA-ACAGNQJTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  93.4
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] SOLUBLE EPOXIDE HYDROLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ÉPOXYDE HYDROLASE SOLUBLE
  申请人：ARETE THERAPEUTICS INC

  公开号：WO2009086429A1

  公开（公告）日：2009-07-09

  Disclosed are amide and urea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.

  揭示了一种抑制可溶性环氧水解酶（sEH）的酰胺和脲类化合物和组合物，以及制备这些化合物和组合物的方法，以及使用这些化合物和组合物治疗患者的方法。这些化合物、组合物和方法可用于治疗各种由sEH介导的疾病，包括高血压、心血管、炎症和糖尿病相关疾病。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
  申请人：Aavula Bhasker R.

  公开号：US20090247521A1

  公开（公告）日：2009-10-01

  The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.
• [EN] SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION<br/>[FR] INHIBITEURS SOLUBLES DE L'ÉPOXYDE HYDROLASE POUR LE TRAITEMENT DE DYSFONCTIONNEMENT ENDOTHÉLIAL
  申请人：ARETE THERAPEUTICS INC

  公开号：WO2009086426A2

  公开（公告）日：2009-07-09

  The present invention generally relates to a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for use in treating and ameliorating the symptoms of diseases related to endothelial dysfunction.